SNDX could be multi-bagger if they can show good Phase III result in Entinostat with other combination.
They also have FDA breakthrough designation which is huge stamp of appreciation from FDA. If drug's indication is cancer and it has BTD status chance of approval is more than 70%.
I have one question though, what is potential peak revenue for Entinostat, if they manage to get FDA approval.
Please do your own due diligence. My post is for information only.
Recent SNDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 01:26:27 PM
- Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress • PR Newswire (US) • 06/14/2024 11:00:00 AM
- Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger • GlobeNewswire Inc. • 06/10/2024 11:30:00 AM
- Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/03/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:04:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:11:37 PM
- Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors • PR Newswire (US) • 05/15/2024 08:05:00 PM
- Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference • PR Newswire (US) • 05/09/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update • PR Newswire (US) • 05/08/2024 11:06:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:04:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:03:25 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 05/03/2024 08:05:00 PM
- Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 • PR Newswire (US) • 05/01/2024 11:00:00 AM
- Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum • PR Newswire (US) • 04/10/2024 08:05:00 PM
- Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session • PR Newswire (US) • 04/08/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 08:05:00 PM
- Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia • PR Newswire (US) • 03/28/2024 11:00:00 AM
- Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia • PR Newswire (US) • 03/26/2024 08:05:00 PM
- Syndax Announces Appointment of Steven Closter as Chief Commercial Officer • PR Newswire (US) • 03/18/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/01/2024 09:05:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/27/2024 10:28:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 10:21:34 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM